Details of the Drug Combination

General Information of Drug Combination (ID: DC7FGX9)

Drug Combination Name
Arfolitixorin TEM
Indication
Disease Entry Status REF
Adenocarcinoma Investigative [1]
Component Drugs Arfolitixorin   DMIXMYK TEM   DMLNFWU
Small molecular drug Small molecular drug
2D MOL 2D MOL
3D MOL 3D MOL
High-throughput Screening Result Testing Cell Line: SW-620
Zero Interaction Potency (ZIP) Score: 4.62
Bliss Independence Score: 6.05
Loewe Additivity Score: 5.24
LHighest Single Agent (HSA) Score: 7.58

Test Results of This Drug Combination in Other Disease Systems

Indication DrugCom ID Cell Line Status REF
Adenocarcinoma DCRJT9G HCT116 Investigative [1]
Large cell lung carcinoma DCS7SA7 NCI-H460 Investigative [1]
Minimally invasive lung adenocarcinoma DCLUYI5 NCI-H322M Investigative [1]
Prostate carcinoma DCZSVYG PC-3 Investigative [1]
------------------------------------------------------------------------------------

References

1 Loss of function mutations in VARS encoding cytoplasmic valyl-tRNA synthetase cause microcephaly, seizures, and progressive cerebral atrophy.Hum Genet. 2018 Apr;137(4):293-303. doi: 10.1007/s00439-018-1882-3. Epub 2018 Apr 24.
2 ClinicalTrials.gov (NCT03750786) A Study to Compare the Efficacy of Arfolitixorin Versus Leucovorin in Combination With 5 Fluorouracil, Oxaliplatin, and Bevacizumab in Patients With Advanced Colorectal Cancer (AGENT). U.S. National Institutes of Health.
3 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800030055)